Identification of anthelmintic parbendazole as a therapeutic molecule for HNSCC through connectivity map-based drug repositioning
Acta Pharmaceutica Sinica B
; (6): 2429-2442, 2022.
Article
Dans En
| WPRIM
| ID: wpr-929395
Responsable en Bibliothèque :
WPRO
ABSTRACT
Head and neck squamous cell carcinoma (HNSCC) is one of the most common human cancers; however, its outcome of pharmacotherapy is always very limited. Herein, we performed a batch query in the connectivity map (cMap) based on bioinformatics, queried out 35 compounds with therapeutic potential, and screened out parbendazole as a most promising compound, which had an excellent inhibitory effect on the proliferation of HNSCC cell lines. In addition, tubulin was identified as a primary target of parbendazole, and the direct binding between them was further verified. Parbendazole was further proved as an effective tubulin polymerization inhibitor, which can block the cell cycle, cause apoptosis and prevent cell migration, and it exhibited reasonable therapeutic effect and low toxicity in the in vivo and in vitro anti-tumor evaluation. Our study repositioned an anthelmintic parbendazole to treat HNSCC, which revealed a therapeutic utility and provided a new treatment option for human cancers.
Texte intégral:
1
Indice:
WPRIM
Type d'étude:
Diagnostic_studies
langue:
En
Texte intégral:
Acta Pharmaceutica Sinica B
Année:
2022
Type:
Article